The Alliance for Regenerative Medicine Released Agenda for Sixth Annual Advanced Therapies Summit - Seite 2

Francis Arickx, Head of Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance
Doug Danison, Head of Global Pricing, Reimbursement, Market Access, and Health Economics, bluebird bio
Leeza Osipenko, Ph.D., Associate Director of Scientific Advice, National Institute for Health & Care Excellence (NICE)
Yaron Ramati, Director of Regulatory Affairs, Pluristem Therapeutics
Constantinos Ziogas, Principal Administrator, European Medicines Agency (EMA)

Roundtable V: ATMP Product Reimbursement
Francis Arickx, Head of Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance
Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Eric Faulkner, Vice President, Precision and Transformative Technology Solutions, Evidera
Alec Orphanidis, SVP, Global Commercial Operations, uniQure
Leeza Osipenko, Ph.D., Associate Director of Scientific Advice, National Institute for Health & Care Excellence (NICE)
Sponsors for the 2016 Advanced Therapies Summit include PharmaCell; TiGenix and TrakCel.

Registration is now open -- to learn more and to secure a spot, please visit ARM's event page. For members of the media interested in attending, please contact Lyndsey Scull ([e-mail]) for information regarding complimentary press registration.

The event will be held at the Scandic Victoria Tower; Arne Beurlings Torg 3; 164 40 Kista, Sweden.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Michelle Linn
774-696-3803
[e-mail]